Schonfeld Strategic Advisors’s iBio IBIO Stock Holding History

Schonfeld Strategic Advisors’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-75	Closed	-$57K	–	2289
2021 Q2	$57K	Buy	+75	New	+$54.7K	﹤0.01%	1867

Other funds holding IBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Schonfeld Strategic Advisors's IBIO Position: Q3 2021 in Review

Schonfeld Strategic Advisors sold out of iBio (IBIO) in Q3 2021, closing a stake of 75 shares — an estimated $57K sold.

Schonfeld Strategic Advisors first reported a position in IBIO in Q2 2021 and held it in 1 quarter. The position peaked at $57K in Q2 2021. 85 funds tracked by Wall St. Rank hold IBIO as of Q3 2021.

Schonfeld Strategic Advisors reported no remaining iBio position as of Q3 2021 after selling out during the quarter.
Schonfeld Strategic Advisors sold 75 iBio shares in Q3 2021, an estimated $57K.
Schonfeld Strategic Advisors first reported a position in iBio in Q2 2021 and held it in 1 quarter.
Schonfeld Strategic Advisors's iBio position peaked at $57K in Q2 2021.
85 funds tracked by Wall St. Rank held iBio as of Q3 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2021, filed 16 Nov 2021.